Piper Sandler analyst Adam Maeder says the Wall Street Journal’s report of potential takeover interest reaffirms the view that ShockWave Medical (SWAV) is an “excellent strategic asset that would fit well within a larger company.” The firm also believes ShockWave is well positioned for continued success as a standalone entity. Piper thinks a potential acquisition by Johnson & Johnson (JNJ) has some strategic merit. However, it believes any acquirer would need to pay a sizable takeout multiple to consummate a deal. Piper views Medtronic (MDT) and Boston Scientific (BSX) as more natural strategic fits than Johnson & Johnson for ShockWave given the companies’ existing broad focus in interventional cardiology and peripheral vascular. As such, the firm would not be surprised to see a competitive process materialize for ShockWave.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWAV:
- M&A News: JNJ Considers Shockwave Buyout
- Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- ShockWave Medical price target raised to $310 from $275 at BofA
- ShockWave Medical price target raised to $286 from $260 at Needham
- ShockWave Medical price target raised to $290 from $275 at Piper Sandler